# Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy

> **NCT01102335** · PHASE4 · UNKNOWN · sponsor: **Fudan University** · enrollment: 80 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** Transcatheter arterial chemoembolization (TACE)
- **DRUG:** Telbivudine

## Key facts

- **NCT ID:** NCT01102335
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-04
- **Primary completion:** 2011-12
- **Final completion:** 2012-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2010-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01102335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01102335, "Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01102335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*